Mountain Group Capital

Mountain Group News

Latest News

Shell Takes a Major Stake in US Solar Developer Silicon Ranch

Shell seeks to expand its global New Energies footprint by acquiring a 44 percent interest in the Nashville-based solar company.

International energy giant Shell has signed a deal to become the largest shareholder of U.S. solar project developer, owner and operator Silicon Ranch Corporation. Under the agreement announced today, Shell will acquire a 43.83 percent interest in Nashville-based Silicon Ranch from Partners Group, a global private markets investment manager. The deal is valued at up to $217 million in cash, based on Silicon Ranch’s performance. Shell has the ability to…

Shell Acquires Interest in Silicon Ranch Corporation

Platform investment aligns Shell with best-in-class U.S. developer, owner, and operator of solar facilities

NASHVILLE, Tenn., Jan. 15, 2018 /PRNewswire/ — Silicon Ranch Corporation, a leading U.S. developer, owner, and operator of solar energy plants, announced today that it has signed an agreement to make Shell its largest shareholder. As part of the agreement, Shell will acquire a 43.83% interest in Silicon Ranch from Partners Group, the global private markets investment manager, for up to $217 million in cash based on Silicon Ranch performance, with the possibility to increase…

AgTech Accelerator Launches First Investment in Novel Fungicide Company, Boragen Inc., with $10 Million Series A Financing

RESEARCH TRIANGLE PARK, N.C. – March 2, 2017 – AgTech AcceleratorTM, the unique startup accelerator vehicle dedicated to emerging agricultural technologies, today announced the launch of its first AgTech startup, Boragen Inc., with a $10 million Series A financing round. Boragen is developing a novel synthetic chemistry platform, initially focusing on next-generation fungicides aimed to mitigate pest resistance and allow for more sustainable farming methods. Boragen’s versatile approach also has…

AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing

AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing AgTech Accelerator Invests in Second Emerging Company RESEARCH TRIANGLE PARK, N.C. – April 13, 2017 – AgTech AcceleratorTM, the RTP- based venture development organization focused on emerging agricultural technology and animal health companies, today announced a $5 million Series A investment into Skyline Vet Pharma, Inc. The investors participating in Skyline’s financing…

G1 Therapeutics Added to Nasdaq Biotechnology Index

RESEARCH TRIANGLE PARK, N.C., Dec. 18, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective prior to market open on Monday, December 18, 2017. The Nasdaq Biotechnology Index (NBI) contains securities of Nasdaq-listed companies classified as either biotechnology or pharmaceutical, according to the Industry Classification Benchmark. Companies in the NBI must…

G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after market close on September 15, 2017, as part of Russell’s quarterly addition of companies with recent initial public offerings. The Russell 2000 Index measures the performance of the small-cap segment of the U.S….

Myomo, Inc. Obtains CE Mark Approval for MyoPro®

Enables Company to Start Providing Devices in Europe

CAMBRIDGE, Mass., July 31, 2017 – Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it has obtained CE Mark approval for commercial sale of its next-generation MyoPro myoelectric arm orthosis across the European Economic Area (EEA). The CE Mark indicates MyoPro complies with the essential requirements of relevant EU legislation and has achieved quality system certification. MyoPro is the only…

G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors

RESEARCH TRIANGLE PARK, N.C., July 13, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the appointment of Sir Andrew Witty to its board of directors. “We are thrilled to welcome Andrew to our board of directors,” said Mark Velleca, MD, PhD, Chief Executive Officer of G1 Therapeutics. “Andrew led and oversaw the development, commercialization, and global market access for several leading pharmaceutical products at…

Biotech company ORIG3N nabs $20 mln

BOSTON, June 27, 2017 – ORIG3N, Inc., a Boston-based biomedical research company, has announced the addition of Byron Smith to its Board of Directors and Spectrum Health Ventures (SHV) to its investor syndicate. The announcements come on the heels of the close of ORIG3N’s latest round of funding. ORIG3N has raised over $30 million in capital to date since it was founded in 2014. Byron Smith brings decades of industry…

Myomo, Inc. Completes Historic Initial Public Offering

First company to go public on the NYSE MKT under JOBS Act Regulation A+

Cambridge, MA., June 9, 2017 – Myomo, Inc. (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the completion of its initial public offering (IPO) under SEC Regulation A+, raising $5.0 Million through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. The Company also closed on a simultaneous private sale of investment units comprised of restricted…

Next Page →